GraniteShares -3x Moderna ETP (SOL3)
Market Closed
14 Aug, 15:30
LSE LSE Primary LSE 43. 77
GBX +3.68
+9.1646%
- Market Cap
- Div Yield
6,593 Volume
40.1 GBX
Previous Close Want to track SOL3 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
SOL3 closed yesterday higher at 43.77 GBX, an increase of 9.1646% from Thursday's close, completing a monthly decrease of -10.2051% or -4.98 GBX. Over the past 12 months, SOL3 stock lost -99.0606%.
SOL3 is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 2 different exchanges and in various currencies, with the primary listing on LSE (GBX).
SOL3 Chart
GraniteShares -3x Moderna ETP (SOL3) FAQ
What is the stock price today?
The current price is 43.77 GBX.
On which exchange is it traded?
GraniteShares -3x Moderna ETP is listed on LSE.
What is its stock symbol?
The ticker symbol is SOL3.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, no market cap data is available.
Has GraniteShares -3x Moderna ETP ever had a stock split?
No, there has never been a stock split.
GraniteShares -3x Moderna ETP Profile
| LSE Exchange | United Kingdom Country |
The GraniteShares -3x Moderna ETP is an exchange-traded product designed for sophisticated investors to capitalize on short-term price fluctuations of Moderna Inc.’s stock through leveraged exposure. The primary function of this ETP is to offer a means for investors to achieve triple inverse leverage against Moderna’s stock, which means that if Moderna's stock decreases in value, the ETP aims to provide a magnified return of three times the inverse of the daily performance of the stock. This makes it a potent tool for hedging or speculative purposes, provided the investor is mindful of the risks associated with leveraged products. Leveraged ETPs like the GraniteShares -3x Moderna can have a significant impact on traders and investors focusing on the biotech sector, particularly those with interests in pharmaceuticals and vaccine technology. In the financial market, such products serve as instruments for managing exposure and implementing advanced trading strategies that require precise control over directional bets on company performance without the need to engage in direct short selling.
Contact Information
Address: -
Phone: -
